Birchview Capital, L.P. 13F annual report
Birchview Capital, L.P. is an investment fund managing more than $108 billion ran by Jack Trottier. There are currently 60 companies in Mr. Trottier’s portfolio. The largest investments include Bristol-Myers Squibb Co and Biodesix Inc, together worth $37.1 billion.
$108 billion Assets Under Management (AUM)
As of 6th August 2024, Birchview Capital, L.P.’s top holding is 688,218 shares of Bristol-Myers Squibb Co currently worth over $28.6 billion and making up 26.5% of the portfolio value.
Relative to the number of outstanding shares of Bristol-Myers Squibb Co, Birchview Capital, L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 5,541,176 shares of Biodesix Inc worth $8.47 billion, whose value grew 1.9% in the past six months.
The third-largest holding is Elutia Inc worth $7.7 billion and the next is Neurocrine Biosciences worth $5.82 billion, with 42,240 shares owned.
Currently, Birchview Capital, L.P.'s portfolio is worth at least $108 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Birchview Capital, L.P.
The Birchview Capital, L.P. office and employees reside in Burlington, Vermont. According to the last 13-F report filed with the SEC, Jack Trottier serves as the CFO, CCO at Birchview Capital, L.P..
Recent trades
In the most recent 13F filing, Birchview Capital, L.P. revealed that it had opened a new position in
Exxon Mobil and bought 5,849 shares worth $673 million.
This means they effectively own approximately 0.1% of the company.
Exxon Mobil makes up
16.2%
of the fund's Energy sector allocation and has decreased its share price by approximately 0.1% in the past year.
The investment fund also strengthened its position in Biodesix Inc by buying
347,840 additional shares.
This makes their stake in Biodesix Inc total 5,541,176 shares worth $8.47 billion.
Biodesix Inc dropped approximately 0.1% in the past year.
On the other hand, there are companies that Birchview Capital, L.P. is getting rid of from its portfolio.
Birchview Capital, L.P. closed its position in Inhibrx on 13th August 2024.
It sold the previously owned 48,448 shares for $1.69 billion.
Jack Trottier also disclosed a decreased stake in Bristol-Myers Squibb Co by approximately 0.1%.
This leaves the value of the investment at $28.6 billion and 688,218 shares.
One of the smallest hedge funds
The two most similar investment funds to Birchview Capital, L.P. are Miramar Fiduciary Corp and Arrowstreet Capital, Limited Partnership. They manage $108 billion and $108 billion respectively.
Jack Trottier investment strategy
Birchview Capital, L.P.’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 80.2% of
the total portfolio value.
The fund focuses on investments in the United States as
73.3% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
10% of the total holdings value.
On the other hand, small-cap stocks make up only 1.7% of the portfolio.
The average market cap of the portfolio companies is close to $15.6 billion.
The complete list of Birchview Capital, L.P. trades based on 13F SEC filings
These positions were updated on August 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Bristol-Myers Squibb Co. |
2.19%
688,218
|
$28,581,696,000 | 26.47% |
| Biodesix Inc |
6.70%
5,541,176
|
$8,470,945,000 | 7.85% |
| Elutia Inc |
6.25%
1,551,655
|
$7,696,209,000 | 7.13% |
| Neurocrine Biosciences, Inc. |
45.31%
42,240
|
$5,815,181,000 | 5.39% |
| Silk Road Medical Inc |
No change
158,094
|
$4,274,862,000 | 3.96% |
| Prothena Corp Plc |
20.05%
203,574
|
$4,201,767,000 | 3.89% |
| Acadia Pharmaceuticals Inc |
No change
250,400
|
$4,069,000,000 | 3.77% |
| Ovintiv Inc |
11.88%
74,200
|
$3,477,754,000 | 3.22% |
| United Therapeutics Corp |
9.09%
10,000
|
$3,185,500,000 | 2.95% |
| Harrow Health, Inc. |
No change
150,000
|
$3,133,500,000 | 2.90% |
| Stoke Therapeutics, Inc. |
No change
210,000
|
$2,837,100,000 | 2.63% |
| Phreesia Inc |
No change
114,700
|
$2,431,640,000 | 2.25% |
| Corcept Therapeutics Inc |
48.00%
74,000
|
$2,404,260,000 | 2.23% |
| QuidelOrtho Corporation |
3.71%
67,619
|
$2,246,303,000 | 2.08% |
| Masimo Corp |
No change
15,280
|
$1,924,363,000 | 1.78% |
| Foghorn Therapeutics Inc. |
No change
320,930
|
$1,845,348,000 | 1.71% |
| Equitrans Midstream Corporatio |
No change
133,050
|
$1,726,989,000 | 1.60% |
| Inhibrx, Inc. |
Closed
48,448
|
$1,693,742,000 | |
| Protagonist Therapeutics Inc |
No change
48,000
|
$1,663,200,000 | 1.54% |
| Axogen Inc. |
13.87%
197,000
|
$1,426,280,000 | 1.32% |
| Docgo Inc |
No change
460,000
|
$1,421,400,000 | 1.32% |
| Alkermes plc |
No change
50,000
|
$1,205,000,000 | 1.12% |
| Travere Therapeutics Inc |
No change
122,000
|
$1,002,840,000 | 0.93% |
| Pioneer Natural Resources Co. |
Closed
3,800
|
$997,500,000 | |
| Alphatec Holdings Inc |
No change
88,000
|
$919,600,000 | 0.85% |
| Castle Biosciences, Inc. |
142.86%
34,000
|
$740,180,000 | 0.69% |
| Exxon Mobil Corp. |
Opened
5,849
|
$673,332,000 | 0.62% |
| Progyny Inc |
No change
22,000
|
$629,420,000 | 0.58% |
| 10x Genomics, Inc. |
No change
30,000
|
$583,500,000 | 0.54% |
| Kiniksa Pharmaceuticals Ltd |
No change
30,000
|
$560,100,000 | 0.52% |
| KalVista Pharmaceuticals Inc |
No change
46,000
|
$541,880,000 | 0.50% |
| Cytokinetics Inc |
No change
10,000
|
$541,800,000 | 0.50% |
| Apellis Pharmaceuticals Inc |
22.22%
14,000
|
$537,040,000 | 0.50% |
| Halozyme Therapeutics Inc. |
No change
10,000
|
$523,600,000 | 0.48% |
| Coherus Biosciences Inc |
No change
270,000
|
$467,100,000 | 0.43% |
| Karyopharm Therapeutics Inc |
No change
469,832
|
$407,626,000 | 0.38% |
| Arvinas Inc |
No change
15,000
|
$399,300,000 | 0.37% |
| Sarepta Therapeutics Inc |
No change
2,500
|
$395,000,000 | 0.37% |
| Xenon Pharmaceuticals Inc |
No change
10,000
|
$389,900,000 | 0.36% |
| Accelerate Diagnostics Inc |
No change
325,239
|
$380,529,000 | 0.35% |
| SpringWorks Therapeutics, Inc. |
No change
10,000
|
$376,700,000 | 0.35% |
| Cullinan Oncology, LLC |
20.36%
20,000
|
$348,800,000 | 0.32% |
| NovoCure Ltd |
Opened
20,000
|
$342,600,000 | 0.32% |
| Axsome Therapeutics Inc |
No change
4,000
|
$322,000,000 | 0.30% |
| Keros Therapeutics, Inc. |
No change
7,000
|
$319,900,000 | 0.30% |
| Bluebird bio Inc |
3.11%
311,200
|
$306,283,000 | 0.28% |
| Amicus Therapeutics Inc |
No change
28,000
|
$277,760,000 | 0.26% |
| Biohaven Pharmaceutical Holding Co Ltd |
No change
7,365
|
$255,639,000 | 0.24% |
| Biocryst Pharmaceuticals Inc. |
100.00%
40,000
|
$247,200,000 | 0.23% |
| Xencor Inc |
No change
12,300
|
$232,839,000 | 0.22% |
| Wave Life Sciences Ltd. |
No change
40,000
|
$199,600,000 | 0.18% |
| G1 Therapeutics Inc |
No change
80,000
|
$182,400,000 | 0.17% |
| Inhibrx Biosciences Inc |
Opened
12,110
|
$170,586,000 | 0.16% |
| Gossamer Bio, Inc. |
No change
138,176
|
$124,483,000 | 0.12% |
| Liquidia Corp |
No change
10,000
|
$120,000,000 | 0.11% |
| Inflarx Nv |
No change
50,000
|
$87,000,000 | 0.08% |
| Cabaletta Bio Inc |
No change
10,000
|
$74,800,000 | 0.07% |
| 2seventy Bio Inc |
10.08%
17,833
|
$68,657,000 | 0.06% |
| Ventyx Biosciences Inc |
No change
28,800
|
$66,528,000 | 0.06% |
| Zentalis Pharmaceuticals, Llc |
No change
16,000
|
$65,440,000 | 0.06% |
| Outset Medical, Inc. |
Opened
10,000
|
$38,500,000 | 0.04% |
| Yield10 Bioscience Inc |
Closed
18,750
|
$7,125,000 | |
| Cero Therapeutics Holdings Inc |
No change
12,972
|
$3,879,000 | 0.00% |
| No transactions found | |||
| Showing first 500 out of 63 holdings | |||
Hedge funds similar to Birchview Capital, L.P.
- Farley Capital L.P.
- Truemark Investments
- Guerra Pan Advisors
- Ltg Capital
- Bey-douglas
- Db Fitzpatrick & Co, Inc
- Arrowstreet Capital, Limited Partnership
- Miramar Fiduciary Corp
- Vanguard Capital Wealth Advisors
- Mayar Capital
- Fmfe Wealth Management
- Newport Capital
- Agincourt Capital Management
- Aldebaran Capital